Patents by Inventor Vinzent Rolny

Vinzent Rolny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers for risk prediction of mortality
    Patent number: 10557858
    Abstract: Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: February 11, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
  • CIRCULATING ESM-1 (ENDOCAN) IN THE ASSESSMENT OF ATRIAL FIBRILLATION AND/OR STROKE
    Publication number: 20190162737
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
    Type: Application
    Filed: February 1, 2019
    Publication date: May 30, 2019
    Applicants: Roche Diagnostics Operations, Inc., Maastricht University Medical Center
    Inventors: Johann Karl, Peter Kastner, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Andre Ziegler, Manuel Dietrich, Ulrich Schotten, Vinzent Rolny
  • METHODS OF DETECTING A RELAPSE OF A LUNG ADENOCARCINOMA BASED ON MARKER HUMAN EPIDIDYMIS PROTEIN 4 (HE4) AND RELATED USES
    Publication number: 20180292410
    Abstract: The present disclosure relates to a method of detecting a relapse of a lung adenocarcinoma in an individual based on marker human epididymis protein 4 (HE4) and optionally Cytokeratin-19 fragments (Cyfra21-1) as well as the use of a marker in the in vitro assessment of a relapse of a lung adenocarcinoma.
    Type: Application
    Filed: June 14, 2018
    Publication date: October 11, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Farshid Dayyani, Friedemann Krause, Achim Escherich, Birgit Wehnl, Ying He, Vinzent Rolny, Sandra Rutz, Thomas Muley, Felix Herth, Julia Riedlinger
  • METHODS OF IDENTIFYING AN INDIVIDUAL TO BE TREATED BY CHEMOTHERAPY BASED ON MARKER MOLECULES AND RELATED USES
    Publication number: 20180231557
    Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.
    Type: Application
    Filed: April 13, 2018
    Publication date: August 16, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Friedemann Krause, Vinzent Rolny, Farshid Dayyani, Achim Escherich, Birgit Wehnl, Ying He, Julia Riedlinger, Felix Herth, Thomas Muley
  • BIOMARKERS AND METHODS OF PREDICTION
    Publication number: 20170322225
    Abstract: Subject of the present invention are biomarkers and methods for the identification of risk for subsequent cardiovascular event (e.g. coronary heart disease death, non-fatal myocardial infarction, ischemic stroke, hospitalizations for unstable angina pectotis, cardiac arrest) in patients that have experienced an acute coronary syndrome, comprising the detecting the level of NT-proBNP, homocysteine and CRP.
    Type: Application
    Filed: April 21, 2017
    Publication date: November 9, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas Dieterle, Eric J. Niesor, Rosemarie Kientsch-Engel, Horst Klima, Fabian Model, Gabriela Bucklar, Vinzent Rolny
  • BIOMARKERS FOR RISK PREDICTION OF MORTALITY
    Publication number: 20170227552
    Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 10, 2017
    Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen